These researchers demonstrated that the inhibition of HIF-2α prevents the in vivo growth and tumorigenesis of highly aggressive glioblastoma, colorectal, and non-small-cell lung carcinomas and the in vitro autonomous proliferation of several other cancers, regardless of their mutational status and tissue of origin. The gene discussed is EPAS1; the disease is non-small cell lung carcinoma.